{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:52Z","timestamp":1788009652257,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40265-017-0794-1","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T05:59:10Z","timestamp":1501653550000},"page":"1493-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab"],"prefix":"10.1007","volume":"77","author":[{"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"issue":"2","key":"794_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/jid.1952.72","volume":"19","author":"MB Sulzberger","year":"1952","unstructured":"Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101\u20132.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"794_CR2","first-page":"555","volume":"301","author":"W Mueller","year":"1979","unstructured":"Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555.","journal-title":"N Engl J Med"},{"issue":"12","key":"794_CR3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14712598.2013.853739","volume":"13","author":"B Mansouri","year":"2013","unstructured":"Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13(12):1715\u201330.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"794_CR4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133\u201342.","journal-title":"Immunology."},{"issue":"3","key":"794_CR5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","volume":"106","author":"T Torres","year":"2015","unstructured":"Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155\u20137.","journal-title":"Actas Dermosifiliogr."},{"issue":"1","key":"794_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","volume":"17","author":"TN Canavan","year":"2016","unstructured":"Canavan TN, Elmets CA, Cantrell WL, Evans JM, Elewski BE. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17(1):33\u201347.","journal-title":"Am J Clin Dermatol."},{"issue":"12","key":"794_CR7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut."},{"issue":"11","key":"794_CR8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"794_CR9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","volume":"15","author":"A Blauvelt","year":"2016","unstructured":"Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413\u201320.","journal-title":"Expert Opin Drug Saf."},{"key":"794_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015","author":"DM Saunte","year":"2016","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol. 2016. doi: 10.1111\/bjd.15015 .","journal-title":"Br J Dermatol."},{"issue":"4","key":"794_CR11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778\u201391.","journal-title":"MAbs."},{"key":"794_CR12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","volume":"67","author":"GE Fragoulis","year":"2016","unstructured":"Fragoulis GE, Siebert S, McInnes IB, Gaffen SL, Jain R, Garg AV, et al. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337\u201353.","journal-title":"Annu Rev Med."},{"key":"794_CR13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"E Toussirot","year":"2014","unstructured":"Toussirot E. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"794_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"E Toussirot","year":"2012","unstructured":"Toussirot E. The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159\u201368.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"5","key":"794_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14728222.2014.889686","volume":"18","author":"A Chiricozzi","year":"2014","unstructured":"Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513\u201325.","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"794_CR16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaad.2013.10.043","volume":"70","author":"AA Levin","year":"2014","unstructured":"Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555\u201361.","journal-title":"J Am Acad Dermatol"},{"key":"794_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"E Lee","year":"2004","unstructured":"Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125\u201330.","journal-title":"J Exp Med"},{"issue":"7","key":"794_CR18","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","volume":"28","author":"P Kulig","year":"2016","unstructured":"Kulig P, Musiol S, Freiberger SN, Schreiner B, Gy\u00fclveszi G, Russo G, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;28(7):13466.","journal-title":"Nat Commun"},{"key":"794_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","volume":"16","author":"MK Gately","year":"1998","unstructured":"Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann Rev Immunol. 1998;16:495\u2013521.","journal-title":"Ann Rev Immunol"},{"issue":"3","key":"794_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","volume":"50","author":"Y Deng","year":"2016","unstructured":"Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):377\u201389.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"1","key":"794_CR21","doi-asserted-by":"crossref","first-page":"116.e7","DOI":"10.1016\/j.jaci.2015.01.018","volume":"136","author":"JG Krueger","year":"2015","unstructured":"Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116.e7\u2013124.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"794_CR22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab\u00a0versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med."},{"issue":"5","key":"794_CR23","first-page":"AB275","volume":"74","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Lacour JP, Menter A, et al. Selective blockade of IL-23p19 with BI 655066 is associated with significant improvement in QoL outcomes compared with ustekinumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017;74(5):AB275.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"794_CR24","first-page":"240","volume":"74","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Lacour JP, Menter A, et al. Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: analysis of scalp, palmoplantar, and nail psoriasis subgroups. J Am Acad Dermatol. 2017;74(5):240.","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 10","key":"794_CR25","first-page":"1","volume":"67","author":"K Papp","year":"2015","unstructured":"Papp K, Menter A, Sofen H, Tyring S, Lacour JP, Berner B, et al. Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis. Arthritis Rheumatol. 2015;67(suppl 10):1\u20134046.","journal-title":"Arthritis Rheumatol"},{"issue":"17","key":"794_CR26","first-page":"30570","volume":"S0140\u20136736","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G, Pan\u00e9s J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor\u00a0risankizumab\u00a0in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;S0140\u20136736(17):30570\u20136.","journal-title":"Lancet."},{"issue":"20","key":"794_CR27","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med."},{"issue":"5","key":"794_CR28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","volume":"10","author":"AC Chan","year":"2010","unstructured":"Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301\u201316.","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"794_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256\u201365.","journal-title":"MAbs."},{"key":"794_CR30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373:136\u201344.","journal-title":"N Engl J Med."},{"key":"794_CR31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331.","journal-title":"J Am Acad Dermatol."},{"key":"794_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317.","journal-title":"J Am Acad Dermatol."},{"key":"794_CR33","doi-asserted-by":"crossref","unstructured":"Gottlieb A, Deodhar A, Boehncke WH, Dong B, Wang Y, Barchuk Y, et al. Efficacy and safety of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis: a phase 2a, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2017; 76:6(suppl 1): AB111.","DOI":"10.1136\/annrheumdis-2017-eular.1164"},{"key":"794_CR34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Thaci D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol. 2015;173:930\u20139.","journal-title":"Br J Dermatol"},{"key":"794_CR35","doi-asserted-by":"crossref","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017; 390(10091):276\u201388.","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"794_CR36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.13437","volume":"172","author":"JE Signorovitch","year":"2015","unstructured":"Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol. 2015;172:504\u201312.","journal-title":"Br J Dermatol."},{"issue":"1","key":"794_CR37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60\u2013699.","journal-title":"J Am Acad Dermatol."},{"key":"794_CR38","doi-asserted-by":"crossref","unstructured":"Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase 3 study. Br J Dermatol. 2017.","DOI":"10.1111\/bjd.15666"},{"issue":"4","key":"794_CR39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","volume":"43","author":"JR Maxwell","year":"2015","unstructured":"Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739\u201350.","journal-title":"Immunity"},{"issue":"4","key":"794_CR40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of followup. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol."},{"issue":"7","key":"794_CR41","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706\u201314.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"794_CR42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin C. Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2016;28(1):66\u201375.","journal-title":"Curr Opin Rheumatol."},{"issue":"11","key":"794_CR43","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZ, Ashcroft DM, Barker JN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632\u201340.","journal-title":"J Invest Dermatol."},{"issue":"9","key":"794_CR44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/PPA.S85773","volume":"16","author":"M Zhang","year":"2015","unstructured":"Zhang M, Brenneman SK, Carter CT, Essoi BL, Farahi K, Johnson MP, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;16(9):777\u201384.","journal-title":"Patient Prefer Adherence."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0794-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:22:52Z","timestamp":1569957772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0794-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0794-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]}}}